Questions across 5 calls

Foram Parekh

Sharekhan

Ajanta Pharma Limited

Ajanta Pharma Limited CC-Mar24.pdf · 2024-05-02

Sir, I just wanted to understand, since you have given a good outlook for the next year in terms of branded generics being able to grow in mid -double-digits and U.S. growth also expected to do good because of shortages and all. And also Red Sea crises is not going to have major impact on the cost. So may I understand why the EBITDA margin guidance is still flat despite the good outlook?

Okay. But in next 2 years down the line, can we expect that goes up above 30%? I mean, since the base is already now at 28%, so can we have this kind of numbers built in?

Laurus Labs Limited

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2024-04-25

Sir, I think you said that in CDMO sales, sales from crop protection and CGT sales would not be a part of sales for the next 1-2 years. Even animal health sales would be after FY27, so with the same amount of CDMO sales, can we assume that EBITDA margin for the next 1-2 years would be in the same range or there is a potential to increase the EBITDA margin. So, how should we look at it?

So, with this, do we at least see 300 plus increase in EBITDA margin and?

Laurus Labs Limited CC-Mar24.pdf · 2024-04-25

Sir, I think you said that in CDMO sales, sales from crop protection and CGT sales would not be a part of sales for the next 1-2 years. Even animal health sales would be after FY27, so with the same amount of CDMO sales, can we assume that EBITDA margin for the next 1-2 years would be in the same range or there is a potential to increase the EBITDA margin. So, how should we look at it?

So, with this, do we at least see 300 plus increase in EBITDA margin and?

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2024-01-24

Thank you for the opportunity. I only have one question. So in the last concall, the management has alluded that H2 would be better than H1. And 9 months down the line, our EBITDA margin is just 15-odd percent. And now in the commentary also, the management did mention that H2 will be significantly better than H1, despite 3 quarters being passed. So are we confident that we will close FY '24 at 20% EBITDA margin as guided in the previous quarter con call?

Okay. So then we see that in the larger pie of [inaudible 0:43:43] segment and commodity prices are softening and also CDMO, which is just 25% of the total sales. So if there's a pickup in CDMO sales too, so you'll be still saying that when the larger pie is not growing, we can still increase our EBITDA margin?

Laurus Labs Limited CC-Dec23.pdf · 2024-01-24

Thank you for the opportunity. I only have one question. So in the last concall, the management has alluded that H2 would be better than H1. And 9 months down the line, our EBITDA margin is just 15-odd percent. And now in the commentary also, the management did mention that H2 will be significantly better than H1, despite 3 quarters being passed. So are we confident that we will close FY '24 at 20% EBITDA margin as guided in the previous quarter con call?

Okay. So then we see that in the larger pie of [inaudible 0:43:43] segment and commodity prices are softening and also CDMO, which is just 25% of the total sales. So if there's a pickup in CDMO sales too, so you'll be still saying that when the larger pie is not growing, we can still increase our EBITDA margin?